Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health services and systems news

Show

From To
The Medicines Patent Pool and Pharco Pharmaceuticals Sign Licence for Promising Hepatitis C Drug Candidate Ravidasvir

The Medicines Patent Pool (MPP) announced a new licence and technology transfer agreement with Egyptian company Pharco Pharmaceuticals for ravidasvir (RAV), an investigational direct-acting antiviral (DAA) with the potential of working across all six major hepatitis C genotypes. The agreement, signed on the sidelines of the International Liver Congress in Amsterdam, will enable competitive supply of RAV in low- and middle-income countries (LMICs) including high prevalence nations Russia, Ukraine, Egypt and Iran.

Published
21 April 2017
From
Medicines Patent Pool
European HCV treatment access survey shows big variations in eligibility

England, Malta, Slovakia, Hungary and Croatia have the tightest restrictions on who can receive direct-acting antiviral (DAA) treatment for hepatitis C, while France, Ireland, Portugal, Germany, Poland

Published
20 April 2017
By
Keith Alcorn
Monitoring of progress towards 90-90-90 blighted by poor quality reporting

Only six countries, representing just 2% of the global HIV burden, have high quality data reporting on the HIV care continuum and progress towards the UNAIDS 90-90-90 target,

Published
20 April 2017
By
Michael Carter
The Future Of Investment In PEPFAR: Understanding PEPFAR’s Multiple Economic, Health, And Diplomatic Impacts

At a time when the future of the program is in doubt due to possibly severe budget cuts to the US State Department (where PEPFAR is based) proposed by the new administration, we thought it would be an opportune moment to highlight some of the key studies we have published exploring PEPFAR’s role in fighting the HIV/AIDS epidemic.

Published
19 April 2017
From
Health Affairs
Open letter to Gilead Sciences about PrEP by EATG and the PrEP in Europe Initiative

Please read and share this letter signed by the European AIDS Treatment Group and the PrEP in Europe Initiative (PEI), a partnership of European prevention and policy NGOs. It requests Gilead Sciences to surrender their patent of Truvada® or otherwise make it possible for Truvada or generic equivalents of it to be offered at greatly reduced prices to all European health care systems so that it can be used as HIV pre-exposure prophylaxis (PrEP).

Published
18 April 2017
From
EATG / PrEP in Europe
Top 10 Pharmaceutical Companies 2017

The global pharmaceutical market was estimated in USD 1.1 trillion in 2016. The top ten pharmaceutical companies in this market had share of around 40% in 2016 and the top 15 approximately 50%. A comparative analysis of the top 15 organisations was used to develop a ranking for these companies. The analysis shows that by far the biggest earners in terms of classes of drugs were oncology drugs and related immune-modulators. Two of the top ten companies featured hepatitis C drugs in their largest earners and one (Gilead) HIV drugs. The HPV vaccine Gardasil also made a lot of money for its developers Merck.

Published
18 April 2017
From
LinkedIn
Destroy Them: One Way to Up Price of Generic Cancer Drugs

In a now-leaked email, a senior executive at a large pharmaceutical company discussed destroying supplies of generic cancer drugs as part of a pricing battle with health authorities in Spain, according to a report in the British newspaper The Times.

Published
18 April 2017
From
Medscape
HIV notifications down 16 per cent in Queensland compared to same period in 2016

There have been 48 HIV notifications in Queensland until April 2, compared with 57 to the same period in 2016.

Published
18 April 2017
From
Brisbane Times
Black HIV-positive MSM in US still have lower rates of ART use

The proportion of newly diagnosed HIV-positive men who have sex with men (MSM) in the United States who were promptly linked to care and started antiretroviral therapy (ART)

Published
17 April 2017
By
Michael Carter
Sex, drugs and activism: making HIV treatment as prevention available in the UK

The Scottish pathway to the PrEP policy decision has been very different to that of England.

Published
13 April 2017
From
Sociology Lens

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.